Department of Biostatistics, Faculty of Medicine, Bezmialem University, Istanbul, Turkey.
Department of Biostatistics, Faculty of Medicine, Amasya University, Amasya, Turkey.
Front Public Health. 2022 Sep 29;10:990848. doi: 10.3389/fpubh.2022.990848. eCollection 2022.
Coronavirus Disease 2019 (COVID-19) disease first appeared in Wuhan, China in December 2019. Subsequently, the pandemic spread rapidly throughout the entire world. The number of people who died from COVID-19 is rising daily due to the growing number cases. This retrospective study aims to classify patients with hepatosteatosis (HS) who had COVID-19, depending on additional disease characteristics and to compare survival times and death rates.
The study included 433 individuals with COVID-19 and HS at Amasya University Sabuncuoglu Serefeddin Education and Research Hospital. Additional disease characteristics of patients with HS were analyzed using latent class analysis (LCA) and the patients were divided into two groups.
The study results indicate that the survival time of the first group, which was formed as a result of the LCA, was significantly lower than that of the second group ( = 0.038). The rate of diabetes, coronary artery disease, chronic rhythm disorder, chronic obstructive pulmonary disease (COPD) and chronic kidney disease was significantly higher in group 1 than in group 2 (respectively < 0.001; < 0.001; < 0.001; < 0.001; = 0.015).
In patients with HS, the presence of diabetes, coronary artery disease, chronic rhythm problem, COPD, and chronic renal disorders contributes to an increase in death rates due to COVID-19.
2019 年 12 月,新型冠状病毒肺炎(COVID-19)疾病首先在中国武汉出现。随后,该疫情迅速在全球范围内蔓延。由于病例不断增加,COVID-19 死亡人数每天都在上升。本回顾性研究旨在根据其他疾病特征对患有肝脂肪变性(HS)的 COVID-19 患者进行分类,并比较生存时间和死亡率。
该研究纳入了在阿马西亚大学萨布努格鲁塞雷芬丁教育与研究医院就诊的 433 例 COVID-19 合并 HS 患者。采用潜在类别分析(LCA)分析 HS 患者的其他疾病特征,并将患者分为两组。
研究结果表明,LCA 形成的第一组的生存时间明显短于第二组(=0.038)。与第二组相比,第一组的糖尿病、冠状动脉疾病、慢性节律障碍、慢性阻塞性肺疾病(COPD)和慢性肾脏病的发生率显著更高(分别为<0.001;<0.001;<0.001;<0.001;=0.015)。
在 HS 患者中,糖尿病、冠状动脉疾病、慢性节律问题、COPD 和慢性肾脏疾病的存在会导致 COVID-19 死亡率增加。